JW Therapeutics Reports Initiation of P-I clinical study for JWATM204 to Treat Advanced Hepatocellular Carcinoma
Shots:
- The company initiates the P-I study to evaluate the safety, tolerability, dose-limited toxicity & PK profile of JWATM204 in patients with HCC. The trial also evaluates the anti-tumor activity in the target population
- The 5yr. survival rate was 15%-19% in North America, ORRs of 17%-20% & 15%-20% for the 1 & 2L therapies in HCC patients. The preclinical studies showed continued clinical development potential of JWATM204 for HCC
- JWATM204 is a GPC-3 mAb created at the ARTEMIS® T-cell platform with high affinity & specificity. The company obtained an in-license from Eureka to develop, manufacture & commercialize JWATM204 in China (incl. mainland China, Hong Kong, Macao & Taiwan) and the member countries of the association of Southeast Asian nations in 2020
Ref: PRNewswire | Image: JW Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
